熱門資訊> 正文
Neumora Therapeutics GAAP每股收益为-0.33美元
2025-08-07 05:53
- Neumora Therapeutics press release (NASDAQ:NMRA): Q2 GAAP EPS of -$0.33.
- Cash Position: As of June 30, 2025, Neumora had cash, cash equivalents and marketable securities of $217.6 million.
- Financial Guidance: The Company expects that its cash, cash equivalents and marketable securities as of June 30, 2025, will enable it to fund its operating plan into 2027.
More on Neumora Therapeutics
- Neumora Therapeutics, Inc. (NMRA) Q1 2025 Earnings Call Transcript
- Seeking Alpha’s Quant Rating on Neumora Therapeutics
- Historical earnings data for Neumora Therapeutics
- Financial information for Neumora Therapeutics
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
